Treatment(s) already received-None Page 2 Posts on Medivizor
Navigation Menu

Treatment(s) already received-None Posts on Medivizor

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Which is more effective in secondary acute myeloid leukemia, FLAG or standard 7+3 induction therapy?

Posted by on Jul 3, 2018 in Leukemia | 0 comments

In a nutshell This study analyzed different types of induction chemotherapy regimes in secondary acute myeloid leukemia. The authors concluded that the FLAG combination had a high response rate and a low level of treatment-related side effects. Some background Secondary acute myeloid leukemia is a type of leukemia arising from a pre-existing...

Read More

Comparing obinutuzumab and rituximab in first-line chemotherapy regimens for follicular lymphoma

Posted by on Jul 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...

Read More

What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?

Posted by on Feb 9, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...

Read More

Quality of life after different types of radiation in early-stage breast cancer

Posted by on Feb 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the impact of whole breast radiation therapy (WBRT) and accelerated partial breast irradiation (APBI) on the severity of post-treatment side effects and quality of life. This study concluded that both forms of radiation therapy (RT) show similar survival benefits and similar quality of life in early-stage breast...

Read More

The impact of cancer-related fatigue on Hodgkin lymphoma patients and survivors

Posted by on Feb 1, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the impact of cancer-related fatigue on Hodgkin-Lymphoma patients and survivors. The authors concluded that fatigue particularly affected social integration.   Some background Hodgkin-Lymphoma (HL) patients and survivors can experience persistent cancer-related fatigue. Reports of fatigue occur 2.5 to 3...

Read More

Who should receive radiotherapy after breast-conserving surgery for ductal carcinoma in situ?

Posted by on Feb 1, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the rate of loco-regional recurrence (LRR) when breast-conserving surgery (BSC) was not followed by radiotherapy. This study concluded that the rate of LRR was low in patients who did not undergo radiation after BCS, but that age and margin width were risk factors for LRR. Some background BCS is a surgery...

Read More

Could immunotherapy be more beneficial than chemotherapy at treating some types of NSCLC?

Posted by on Dec 19, 2016 in Lung cancer | 0 comments

In a nutshell This trial determined whether pembrolizumab (Keytruda) is more effective at treating advanced NSCLC than chemotherapy in patients with high levels of a specific protein called PD-L1. The authors concluded that, for this subgroup of patients, pembrolizumab was more effective and safer than chemotherapy. Some background In some...

Read More